Interplay of PA-X and NS1 proteins in replication and pathogenesis of a temperature-sensitive 2009 pandemic H1N1 influenza A virus

Journal of Virology

Volumn 91, Issue 17, 2017, Pages

  Nogales, Aitor ^a   Rodriguez, Laura ^a   DeDiego, Marta L ^a,b   Topham, David J ^a,b   Martínez Sobrido, Luis ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Host response; Influenza; Influenza vaccines; Virus host interactions

Indexed keywords

CELL PROTEIN; INFLUENZA VACCINE; NONSTRUCTURAL PROTEIN 1; PA-X PROTEIN; UNCLASSIFIED DRUG; INS1 PROTEIN, INFLUENZA VIRUS; PA-X PROTEIN, INFLUENZA A VIRUS; REPRESSOR PROTEIN; VIRAL PROTEIN;

2009 H1N1 INFLUENZA; ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRAMESHIFT MUTATION; GENE EXPRESSION; IMMUNE RESPONSE; IN VIVO STUDY; INFLUENZA A VIRUS (H1N1); INNATE IMMUNITY; MOUSE; NONHUMAN; OPEN READING FRAME; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; TEMPERATURE SENSITIVITY; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS VIRULENCE; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DNA REPLICATION; GENETICS; HEK293 CELL LINE; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY; PRECLINICAL STUDY; PROTEIN SYNTHESIS; TEMPERATURE; VIROLOGY;

ANIMALS; DNA REPLICATION; DRUG EVALUATION, PRECLINICAL; FEMALE; HEK293 CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN BIOSYNTHESIS; REPRESSOR PROTEINS; TEMPERATURE; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 85027374646     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00720-17     Document Type: Article

References (70)

1. Palese P, Shaw ML. 2007. Orthomyxoviridae: the viruses and their replication. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA (ed), Fields virology, 5th ed. Lippincott Williams and Wilkins, Philadelphia, PA
2. Resa-Infante P, Jorba N, Coloma R, Ortin J. 2011. The influenza virus RNA synthesis machine: advances in its structure and function. RNA Biol 8:207-215. https://doi.org/10.4161/rna.8.2.14513
3. Wong SS, Webby RJ. 2013. Traditional and new influenza vaccines. Clin Microbiol Rev 26:476-492. https://doi.org/10.1128/CMR.00097-12
4. Chan W, Zhou H, Kemble G, Jin H. 2008. The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature. Virology 380:304-311. https://doi.org/10.1016/j.virol.2008.07.027
5. Cox NJ, Kitame F, Kendal AP, Maassab HF, Naeve C. 1988. Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2). Virology 167:554-567
6. Snyder MH, Betts RF, DeBorde D, Tierney EL, Clements ML, Herrington D, Sears SD, Dolin R, Maassab HF, Murphy BR. 1988. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 62:488-495
7. Cox A, Baker SF, Nogales A, Martinez-Sobrido L, Dewhurst S. 2015. Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine. J Virol 89:3421-3426. https://doi.org/10.1128/JVI.02636-14
8. Jin H, Zhou H, Lu B, Kemble G. 2004. Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from coldadapted A/Ann Arbor/6/60. J Virol 78:995-998. https://doi.org/10.1128/JVI.78.2.995-998.2004
9. Nogales A, Rodriguez L, Chauche C, Huang K, Reilly EC, Topham DJ, Murcia PR, Parrish CR, Martinez-Sobrido L. 31 January 2017. Temperature-sensitive live-attenuated canine influenza virus H3N8 vaccine. J Virol https://doi.org/10.1128/JVI.02211-16
10. Rodriguez L, Nogales A, Reilly EC, Topham DJ, Murcia PR, Parrish CR, Martinez Sobrido L. 2017. A live-attenuated influenza vaccine for H3N2 canine influenza virus. Virology 504:96-106. https://doi.org/10.1016/j.virol.2017.01.020
11. Zhou B, Li Y, Speer SD, Subba A, Lin X, Wentworth DE. 2012. Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses. Vaccine 30:3691-3702. https://doi.org/10.1016/j.vaccine.2012.03.025
12. Iwasaki A, Pillai PS. 2014. Innate immunity to influenza virus infection. Nat Rev Immunol 14:315-328. https://doi.org/10.1038/nri3665
13. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P, Muster T. 1998. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252:324-330. https://doi.org/10.1006/viro.1998.9508
14. Hale BG, Randall RE, Ortin J, Jackson D. 2008. The multifunctional NS1 protein of influenza A viruses. J Gen Virol 89:2359-2376. https://doi.org/10.1099/vir.0.2008/004606-0
15. Jagger BW, Wise HM, Kash JC, Walters KA, Wills NM, Xiao YL, Dunfee RL, Schwartzman LM, Ozinsky A, Bell GL, Dalton RM, Lo A, Efstathiou S, Atkins JF, Firth AE, Taubenberger JK, Digard P. 2012. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science 337:199-204. https://doi.org/10.1126/science.1222213
16. Hu J, Mo Y, Wang X, Gu M, Hu Z, Zhong L, Wu Q, Hao X, Hu S, Liu W, Liu H, Liu X, Liu X. 2015. PA-X decreases the pathogenicity of highly pathogenic H5N1 influenza A virus in avian species by inhibiting virus replication and host response. J Virol 89:4126-4142. https://doi.org/10.1128/JVI.02132-14
17. Khaperskyy DA, McCormick C. 2015. Timing is everything: coordinated control of host shutoffby influenza A virus NS1 and PA-X proteins. J Virol 89:6528-6531. https://doi.org/10.1128/JVI.00386-15
18. Khaperskyy DA, Schmaling S, Larkins-Ford J, McCormick C, Gaglia MM. 2016. Selective degradation of host RNA polymerase II transcripts by influenza A virus PA-X host shutoffprotein. PLoS Pathog 12:e1005427. https://doi.org/10.1371/journal.ppat.1005427
19. Oishi K, Yamayoshi S, Kawaoka Y. 2015. Mapping of a region of the PA-X protein of influenza A virus that is important for its shutoffactivity. J Virol 89:8661-8665. https://doi.org/10.1128/JVI.01132-15
20. Gao H, Sun H, Hu J, Qi L, Wang J, Xiong X, Wang Y, He Q, Lin Y, Kong W, Seng LG, Pu J, Chang KC, Liu X, Liu J, Sun Y. 2015. Twenty amino acids at the C-terminus of PA-X are associated with increased influenza A virus replication and pathogenicity. J Gen Virol 96:2036-2049. https://doi.org/10.1099/vir.0.000143
21. Gao H, Xu G, Sun Y, Qi L, Wang J, Kong W, Sun H, Pu J, Chang KC, Liu J. 2015. PA-X is a virulence factor in avian H9N2 influenza virus. J Gen Virol 96:2587-2594. https://doi.org/10.1099/jgv.0.000232
22. Hu J, Mo Y, Gao Z, Wang X, Gu M, Liang Y, Cheng X, Hu S, Liu W, Liu H, Chen S, Liu X, Peng D, Liu X. 2016. PA-X-associated early alleviation of the acute lung injury contributes to the attenuation of a highly pathogenic H5N1 avian influenza virus in mice. Med Microbiol Immunol 205:381-395. https://doi.org/10.1007/s00430-016-0461-2
23. Bavagnoli L, Cucuzza S, Campanini G, Rovida F, Paolucci S, Baldanti F, Maga G. 2015. The novel influenza A virus protein PA-X and its naturally deleted variant show different enzymatic properties in comparison to the viral endonuclease PA. Nucleic Acids Res 43:9405-9417. https://doi.org/10.1093/nar/gkv926
24. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, Staeheli P, Wack A. 2013. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenzainfected airway epithelia. PLoS Pathog 9:e1003773. https://doi.org/10.1371/journal.ppat.1003773
25. DeDiego ML, Nogales A, Lambert-Emo K, Martinez-Sobrido L, Topham DJ. 2016. NS1 protein mutation I64T affects interferon responses and virulence of circulating H3N2 human influenza A viruses. J Virol 90: 9693-9711. https://doi.org/10.1128/JVI.01039-16
26. Nogales A, Martinez-Sobrido L, Topham DJ, DeDiego ML. 14 February 2017. NS1 protein amino acid changes D189N and V194I affect interferon responses, thermosensitivity and virulence of circulating H3N2 human influenza A viruses. J Virol https://doi.org/10.1128/JVI.01930-16
27. WolffT, Ludwig S. 2009. Influenza viruses control the vertebrate type I interferon system: factors, mechanisms, and consequences. J Interferon Cytokine Res 29:549-557. https://doi.org/10.1089/jir.2009.0066
28. Das K, Ma LC, Xiao R, Radvansky B, Aramini J, Zhao L, Marklund J, Kuo RL, Twu KY, Arnold E, Krug RM, Montelione GT. 2008. Structural basis for suppression of a host antiviral response by influenza A virus. Proc Natl Acad Sci U S A 105:13093-13098. https://doi.org/10.1073/pnas.0805213105
29. Kochs G, Garcia-Sastre A, Martinez-Sobrido L. 2007. Multiple antiinterferon actions of the influenza A virus NS1 protein. J Virol 81: 7011-7021. https://doi.org/10.1128/JVI.02581-06
30. Noah DL, Twu KY, Krug RM. 2003. Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3= end processing of cellular pre-mRNAS. Virology 307:386-395. https://doi.org/10.1016/S0042-6822(02)00127-7
31. Ayllon J, Domingues P, Rajsbaum R, Miorin L, Schmolke M, Hale BG, Garcia-Sastre A. 2014. A single amino acid substitution in the novel H7N9 influenza A virus NS1 protein increases CPSF30 binding and virulence. J Virol 88:12146-12151. https://doi.org/10.1128/JVI.01567-14
32. NemeroffME, Barabino SM, Li Y, Keller W, Krug RM. 1998. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3=end formation of cellular pre-mRNAs. Mol Cell 1:991-1000. https://doi.org/10.1016/S1097-2765(00)80099-4
33. Twu KY, Noah DL, Rao P, Kuo RL, Krug RM. 2006. The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target. J Virol 80:3957-3965. https://doi.org/10.1128/JVI.80.8.3957-3965.2006
34. Hale BG, Steel J, Medina RA, Manicassamy B, Ye J, Hickman D, Hai R, Schmolke M, Lowen AC, Perez DR, Garcia-Sastre A. 2010. Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein. J Virol 84:6909-6922. https://doi.org/10.1128/JVI.00081-10
35. Lee J, Yu H, Li Y, Ma J, Lang Y, DuffM, Henningson J, Liu Q, Li Y, Nagy A, Bawa B, Li Z, Tong G, Richt JA, Ma W. 2017. Impacts of different expressions of PA-X protein on 2009 pandemic H1N1 virus replication, pathogenicity and host immune responses. Virology 504:25-35. https://doi.org/10.1016/j.virol.2017.01.015
36. Louie JK, Jean C, Acosta M, Samuel MC, Matyas BT, Schechter R. 2011. A review of adult mortality due to 2009 pandemic (H1N1) influenza A in California. PLoS One 6:e18221. https://doi.org/10.1371/journal.pone.0018221
37. Seibert CW, Kaminski M, Philipp J, Rubbenstroth D, Albrecht RA, Schwalm F, Stertz S, Medina RA, Kochs G, Garcia-Sastre A, Staeheli P, Palese P. 2010. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol 84:11219-11226. https://doi.org/10.1128/JVI.01424-10
38. Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, Van Kerkhove MD, Mounts AW, Paget WJ, Teams GLC. 2013. Global mortality estimates for the 2009 influenza pandemic from the GLaMOR project: a modeling study. Plos Med 10:e1001558. https://doi.org/10.1371/journal.pmed.1001558
39. Nogales A, Martinez-Sobrido L. 22 December 2016. Reverse genetics approaches for the development of influenza vaccines. Int J Mol Sci https://doi.org/10.3390/ijms18010020
40. Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, Bresee JS. 2016. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep 65:1-54. https://doi.org/10.15585/mmwr.rr6505a1
41. Principi N, Esposito S. 2017. Protection of children against influenza: emerging problems. Hum Vaccines Immunother 2017:1-8. https://doi.org/10.1080/21645515.2017.1279772
42. Feng KH, Sun M, Iketani S, Holmes EC, Parrish CR. 2016. Comparing the functions of equine and canine influenza H3N8 virus PA-X proteins: suppression of reporter gene expression and modulation of global host gene expression. Virology 496:138-146. https://doi.org/10.1016/j.virol.2016.06.001
43. Gao H, Sun Y, Hu J, Qi L, Wang J, Xiong X, Wang Y, He Q, Lin Y, Kong W, Seng LG, Sun H, Pu J, Chang KC, Liu X, Liu J. 2015. The contribution of PA-X to the virulence of pandemic 2009 H1N1 and highly pathogenic H5N1 avian influenza viruses. Sci Rep 5:8262. https://doi.org/10.1038/srep08262
44. Geiss GK, Salvatore M, Tumpey TM, Carter VS, Wang X, Basler CF, Taubenberger JK, Bumgarner RE, Palese P, Katze MG, Garcia-Sastre A. 2002. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A 99:10736-10741. https://doi.org/10.1073/pnas.112338099
45. Konig R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, Garcia-Sastre A, Young JA, Palese P, Shaw ML, Chanda SK. 2010. Human host factors required for influenza virus replication. Nature 463:813-817. https://doi.org/10.1038/nature08699
46. Dove BK, Surtees R, Bean TJ, Munday D, Wise HM, Digard P, Carroll MW, Ajuh P, Barr JN, Hiscox JA. 2012. A quantitative proteomic analysis of lung epithelial (A549) cells infected with 2009 pandemic influenza A virus using stable isotope labelling with amino acids in cell culture. Proteomics 12:1431-1436. https://doi.org/10.1002/pmic.201100470
47. Sutejo R, Yeo DS, Myaing MZ, Hui C, Xia J, Ko D, Cheung PC, Tan BH, Sugrue RJ. 2012. Activation of type I and III interferon signalling pathways occurs in lung epithelial cells infected with low pathogenic avian influenza viruses. PLoS One 7:e33732. https://doi.org/10.1371/journal.pone.0033732
48. Hai R, Martinez-Sobrido L, Fraser KA, Ayllon J, Garcia-Sastre A, Palese P. 2008. Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol 82:10580-10590. https://doi.org/10.1128/JVI.01213-08
49. Nogales A, Baker SF, Ortiz-Riano E, Dewhurst S, Topham DJ, Martinez-Sobrido L. 2014. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. J Virol 88:10525-10540. https://doi.org/10.1128/JVI.01565-14
50. Martinez-Sobrido L, Emonet S, Giannakas P, Cubitt B, Garcia-Sastre A, de la Torre JC. 2009. Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 83:11330-11340. https://doi.org/10.1128/JVI.00763-09
51. Martinez-Sobrido L, Zuniga EI, Rosario D, Garcia-Sastre A, de la Torre JC. 2006. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 80:9192-9199. https://doi.org/10.1128/JVI.00555-06
52. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am J Hyg 27:493-497
53. Tavares LP, Teixeira MM, Garcia CC. 2017. The inflammatory response triggered by Influenza virus: a two edged sword. Inflamm Res 66: 283-302. https://doi.org/10.1007/s00011-016-0996-0
54. Wang Z, Loh L, Kedzierski L, Kedzierska K. 2016. Avian influenza viruses, inflammation, and CD8(+) T cell immunity. Front Immunol 7:60. https://doi.org/10.3389/fimmu.2016.00060
55. Baker SF, Guo H, Albrecht RA, Garcia-Sastre A, Topham DJ, Martinez-Sobrido L. 2013. Protection against lethal influenza with a viral mimic. J Virol 87:8591-8605. https://doi.org/10.1128/JVI.01081-13
56. Tripathi S, Batra J, Lal SK. 2015. Interplay between influenza A virus and host factors: targets for antiviral intervention. Arch Virol 160:1877-1891. https://doi.org/10.1007/s00705-015-2452-9
57. Watanabe T, Kawaoka Y. 2015. Influenza virus-host interactomes as a basis for antiviral drug development. Curr Opin Virol 14:71-78. https://doi.org/10.1016/j.coviro.2015.08.008
58. Hai R, Schmolke M, Varga ZT, Manicassamy B, Wang TT, Belser JA, Pearce MB, Garcia-Sastre A, Tumpey TM, Palese P. 2010. PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J Virol 84:4442-4450. https://doi.org/10.1128/JVI.02717-09
59. Martinez-Sobrido L, Garcia-Sastre A. 3 August 2010. Generation of recombinant influenza virus from plasmid DNA. J Vis Exp https://doi.org/10.3791/2057
60. Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, Garcia-Sastre A, Basler CF. 2003. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol 77:1501-1511. https://doi.org/10.1128/JVI.77.2.1501-1511.2003
61. Quinlivan M, Zamarin D, Garcia-Sastre A, Cullinane A, Chambers T, Palese P. 2005. Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol 79:8431-8439. https://doi.org/10.1128/JVI.79.13.8431-8439.2005
62. Baker SF, Nogales A, Finch C, Tuffy KM, Domm W, Perez DR, Topham DJ, Martinez-Sobrido L. 2014. Influenza A and B virus intertypic reassortment through compatible viral packaging signals. J Virol 88:10778-10791. https://doi.org/10.1128/JVI.01440-14
63. Nogales A, Baker SF, Martinez-Sobrido L. 2014. Replication-competent influenza A viruses expressing a red fluorescent protein. Virology 476C: 206-216
64. Capul AA, de la Torre JC. 2008. A cell-based luciferase assay amenable to high-throughput screening of inhibitors of arenavirus budding. Virology 382:107-114. https://doi.org/10.1016/j.virol.2008.09.008
65. Cheng BY, Ortiz-Riano E, Nogales A, de la Torre JC, Martinez-Sobrido L. 2015. Development of live-attenuated arenavirus vaccines based on codon deoptimization. J Virol 89:3523-3533. https://doi.org/10.1128/JVI.03401-14
66. Nakajima Y, Kobayashi K, Yamagishi K, Enomoto T, Ohmiya Y. 2004. cDNA cloning and characterization of a secreted luciferase from the luminous Japanese ostracod, Cypridina noctiluca. Biosci Biotechnol Biochem 68:565-570. https://doi.org/10.1271/bbb.68.565
67. Solorzano A, Webby RJ, Lager KM, Janke BH, Garcia-Sastre A, Richt JA. 2005. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol 79: 7535-7543. https://doi.org/10.1128/JVI.79.12.7535-7543.2005
68. Nogales A, Rodriguez-Sanchez I, Monte K, Lenschow DJ, Perez DR, Martinez-Sobrido L. 2016. Replication-competent fluorescent-expressing influenza B virus. Virus Res 213:69-81. https://doi.org/10.1016/j.virusres.2015.11.014
69. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC
70. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) method. Methods 25:402-408. https://doi.org/10.1006/meth.2001.1262